TABLE 2.
Group mean absolute percentage difference and standard deviation of VT, BPP, and occupancy estimated with the proposed AC methods with respect to AC CT for every ROI.
| Mean AD (%) | Temporal | ACC | Amygdala | Caudate | Putamen | Thalamus | Cerebellum |
| AC DIXON | |||||||
| VT placebo | 11.0 ± 1.7 | 9.7 ± 2.3 | 6.4 ± 1.4 | 7.8 ± 1.4 | 8.2 ± 1.4 | 8.4 ± 1.6 | 11.7 ± 2.6 |
| VT SSRI | 11.1 ± 1.6 | 9.2 ± 1.6 | 6.1 ± 1.7 | 7.0 ± 1.6 | 7.6 ± 1.5 | 7.7 ± 1.5 | 11.8 ± 2.7 |
| BPP placebo | 9.2 ± 3.5 | 7.0 ± 5.2 | 2.8 ± 1.6 | 5.0 ± 1.9 | 5.9 ± 1.8 | 6.6 ± 1.9 | − |
| BPP SSRI | 10.8 ± 7.2 | 14.5 ± 16.8 | 9.2 ± 9.5 | 3.7 ± 3.4 | 2.8 ± 2.2 | 3.4 ± 2.7 | − |
| Occupancy | 6.7 ± 6.5 | 11.7 ± 13.9 | 4.7 ± 2.7 | 3.7 ± 2.1 | 3.0 ± 2.0 | 2.7 ± 1.6 | − |
| AC UTE | |||||||
| VT placebo | 6.5 ± 1.7 | 7.1 ± 1.2 | 4.1 ± 1.8 | 3.9 ± 1.4 | 4.2 ± 1.4 | 3.5 ± 1.4 | 9.0 ± 2.8 |
| VT SSRI | 6.5 ± 2.0 | 7.1 ± 1.0 | 4.3 ± 2.2 | 4.2 ± 1.5 | 4.4 ± 1.4 | 3.5 ± 1.6 | 9.0 ± 2.9 |
| BPP placebo | 5.1 ± 2.8 | 6.0 ± 3.9 | 1.6 ± 1.4 | 1.1 ± 0.8 | 1.4 ± 1.1 | 1.1 ± 0.8 | − |
| BPP SSRI | 11.7 ± 9.7 | 15.1 ± 17.0 | 9.4 ± 8.8 | 5.0 ± 4.1 | 4.0 ± 3.0 | 5.2 ± 3.9 | − |
| Occupancy | 8.3 ± 5.2 | 8.5 ± 5.6 | 3.2 ± 2.1 | 2.4 ± 1.6 | 2.2 ± 1.6 | 2.5 ± 1.4 | − |
| AC pseudoCT | |||||||
| VT placebo | 1.5 ± 1.7 | 1.3 ± 1.2 | 1.5 ± 1.4 | 1.8 ± 1.4 | 1.9 ± 1.5 | 1.2 ± 1.5 | 2.5 ± 1.6 |
| VT SSRI | 1.5 ± 1.7 | 1.2 ± 0.9 | 1.7 ± 1.7 | 1.4 ± 1.1 | 1.4 ± 1.2 | 1.2 ± 1.2 | 2.5 ± 1.6 |
| BPP placebo | 5.1 ± 5.3 | 6.9 ± 4.1 | 2.0 ± 1.8 | 2.9 ± 1.9 | 2.5 ± 2.0 | 1.6 ± 1.8 | − |
| BPP SSRI | 9.2 ± 9.7 | 16.5 ± 15.2 | 4.3 ± 3.7 | 3.6 ± 2.4 | 3.6 ± 2.1 | 3.1 ± 2.3 | − |
| Occupancy | 5.1 ± 5.7 | 7.5 ± 4.9 | 1.3 ± 0.9 | 1.6 ± 1.5 | 1.6 ± 1.3 | 1.3 ± 1.2 | − |
| AC RESOLUTE | |||||||
| VT placebo | 4.5 ± 1.3 | 1.9 ± 0.9 | 5.3 ± 1.8 | 3.8 ± 1.3 | 3.8 ± 1.1 | 3.4 ± 1.0 | 2.8 ± 1.8 |
| VT SSRI | 4.4 ± 1.5 | 2.2 ± 0.7 | 5.2 ± 1.5 | 4.1 ± 1.1 | 4.5 ± 1.1 | 4.2 ± 1.1 | 2.6 ± 1.6 |
| BPP placebo | 10.5 ± 5.9 | 5.4 ± 4.5 | 8.0 ± 3.1 | 5.0 ± 1.9 | 4.7 ± 1.5 | 4.0 ± 1.4 | − |
| BPP SSRI | 16.6 ± 10.4 | 13.7 ± 15.2 | 13.4 ± 6.6 | 7.5 ± 3.2 | 8.0 ± 3.3 | 7.3 ± 3.3 | − |
| Occupancy | 6.0 ± 4.7 | 6.8 ± 4.3 | 2.6 ± 1.5 | 1.7 ± 1.7 | 2.0 ± 1.6 | 1.7 ± 1.1 | − |
| AC BD | |||||||
| VT placebo | 6.0 ± 1.6 | 4.6 ± 2.4 | 2.5 ± 1.4 | 3.9 ± 1.6 | 4.3 ± 1.6 | 4.7 ± 1.8 | 4.3 ± 2.8 |
| VT SSRI | 6.5 ± 1.6 | 4.1 ± 1.7 | 2.9 ± 1.7 | 3.6 ± 1.8 | 4.0 ± 1.7 | 4.4 ± 1.7 | 5.2 ± 3.2 |
| BPP placebo | 11.1 ± 5.0 | 8.3 ± 6.2 | 2.6 ± 1.9 | 3.6 ± 2.2 | 4.4 ± 2.0 | 4.9 ± 2.1 | − |
| BPP SSRI | 16.1 ± 9.3 | 14.3 ± 11.5 | 5.0 ± 5.0 | 4.2 ± 4.0 | 3.8 ± 3.3 | 4.7 ± 3.4 | − |
| Occupancy | 10.9 ± 12.7 | 16.2 ± 20.5 | 2.1 ± 1.7 | 3.1 ± 2.3 | 2.7 ± 2.3 | 2.3 ± 1.6 | − |